Altre lingue AtriCure, Inc.

Azioni

ATRC

US04963C2098

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 18/04/2024			Variaz. 5gg	Var. 1 gen.
23,39 ^USD	-0,26%		-7,59%	-34,46%

18/04	AtriCure, Inc. annuncia il lancio della sonda CryoSPHERE®?+ per la gestione del dolore post-operatorio	CI
07/03	Un insider di AtriCure ha venduto azioni per un valore di 307.510 dollari, secondo un recente documento della SEC	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management	18/04
AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management	18/04
AtriCure to Announce First Quarter 2024 Financial Results	10/04
AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference	26/03
AtriCure Insider Sold Shares Worth $307,510, According to a Recent SEC Filing	07/03
Atricure, Inc. Appoints Shlomi Nachman as Director, Member of Each of the Board?s Strategy Committee and Compliance, Quality and Risk Committee	27/02
AtriCure Q4 Loss Widens, Revenue Rises; 2024 Guidance Set	15/02
Earnings Flash (ATRC) ATRICURE Reports Q4 Revenue $106.5M, vs. Street Est of $104.2M	15/02
AtriCure: Q4 Earnings Snapshot	15/02
AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results	15/02
Atricure, Inc. Provides Earnings Guidance for 2024	15/02
AtriCure, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	15/02
AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference	25/01
AtriCure Reports Higher Preliminary Q4, 2023 Revenue; Issues 2024 Revenue Guidance; Shares Rise	08/01
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2023, Provides Financial Outlook for 2024	08/01
AtriCure, Inc. and Its Wholly Owned Subsidiary, Atricure, LLC Enters into an Asset-Based Credit Agreement	08/01
Atricure, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Provides Financial Guidance for the Year 2024	08/01
AtriCure Appoints Shlomi Nachman to the Board of Directors	04/01
AtriCure, Inc. Appoints Shlomi Nachman to its Board of Directors	04/01
AtriCure to Participate in the 42nd Annual J.P. Morgan Healthcare Conference	20/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue AtriCure, Inc.

Azioni

ATRC

US04963C2098

Altre lingue

Filtri